Stockreport

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Zura Bio Limited - Class A Ordinary shares  (ZURA) 
PDF Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025Cash, cash [Read more]